The post Kraken weighs U.S. IPO timing as CFTC clarity evolves appeared on BitcoinEthereumNews.com. Did Kraken halt its IPO? Kraken IPO looks delayed, not haltedThe post Kraken weighs U.S. IPO timing as CFTC clarity evolves appeared on BitcoinEthereumNews.com. Did Kraken halt its IPO? Kraken IPO looks delayed, not halted

Kraken weighs U.S. IPO timing as CFTC clarity evolves

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Did Kraken halt its IPO? Kraken IPO looks delayed, not halted

A claim that Kraken’s parent company halted multi-billion-dollar IPO plans is not corroborated by primary disclosures. Available reporting points to a strategic delay rather than a formal halt.

Leadership messaging and capital position support staying private until conditions align. According to Cointelegraph, co-CEO Arjun Sethi has emphasized the company is not in a rush to pursue a U.S. listing.

Why it matters: U.S. crypto regulation, leadership stance, capital strength

As reported by CoinDesk, analysts view potential Commodity Futures Trading Commission oversight as a key gate for U.S. listings. They also note an IPO could take roughly six months after filing, given standard review cycles.

Based on data from Coinpaper, Kraken secured an approximate $15 billion private valuation in 2024, reinforcing a no-rush posture. Strong financing options and operating performance reduce the need to access public equity immediately.

Leadership has framed readiness, risk controls, and governance as prerequisites to any listing. That stance indicates timing will reflect regulatory clarity and internal milestones rather than peer actions or market hype.

Immediate impact: expectations reset and timelines remain conditional

Near-term expectations are shifting from imminent listing to patient evaluation. There is no confirmed IPO date, and communications indicate pacing will track U.S. policy visibility and operational readiness.

Given supervisory review cycles and market window constraints, sequencing could extend. Any filing, roadshow, and pricing cadence would likely be calibrated to those dependencies.

What could change Kraken’s IPO calculus next

Regulatory clarity under the CFTC as a gating factor

A durable framework placing key crypto spot markets under the Commodity Futures Trading Commission could reduce jurisdictional uncertainty. Clear registration pathways and supervisory expectations would lower legal risk, improving listing feasibility.

Arjun Sethi’s public stance on timing and readiness

Public comments from co-CEO Arjun Sethi emphasize operational readiness over speed, signaling the firm will move only when conditions align.

“We won’t race to the door to get an IPO done,” said Arjun Sethi, co-CEO of Kraken, as reported by Yahoo Finance.

FAQ about Kraken IPO

What is the latest update on a Kraken IPO date or timeline?

No confirmed date. Available reporting indicates delay, not a formal halt, with timing dependent on U.S. regulatory clarity and internal readiness.

Which regulatory developments (e.g., CFTC oversight) could unlock a Kraken listing?

Progress toward clearer CFTC oversight and defined exchange registration frameworks could unlock next steps, but sequencing would remain conditional on reviews and market windows.

Source: https://coincu.com/news/kraken-weighs-u-s-ipo-timing-as-cftc-clarity-evolves/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference

Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference

The post Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference appeared on BitcoinEthereumNews.com. The suitcoiners are in town.  From a low-key, circular podium in the middle of a lavish New York City event hall, Strategy executive chairman Michael Saylor took the mic and opened the Bitcoin Treasuries Unconference event. He joked awkwardly about the orange ties, dresses, caps and other merch to the (mostly male) audience of who’s-who in the bitcoin treasury company world.  Once he got onto the regular beat, it was much of the same: calm and relaxed, speaking freely and with confidence, his keynote was heavy on the metaphors and larger historical stories. Treasury companies are like Rockefeller’s Standard Oil in its early years, Michael Saylor said: We’ve just discovered crude oil and now we’re making sense of the myriad ways in which we can use it — the automobile revolution and jet fuel is still well ahead of us.  Established, trillion-dollar companies not using AI because of “security concerns” make them slow and stupid — just like companies and individuals rejecting digital assets now make them poor and weak.  “I’d like to think that we understood our business five years ago; we didn’t.”  We went from a defensive investment into bitcoin, Saylor said, to opportunistic, to strategic, and finally transformational; “only then did we realize that we were different.” Michael Saylor: You Come Into My Financial History House?! Jokes aside, Michael Saylor is very welcome to the warm waters of our financial past. He acquitted himself honorably by invoking the British Consol — though mispronouncing it, and misdating it to the 1780s; Pelham’s consolidation of debts happened in the 1750s and perpetual government debt existed well before then — and comparing it to the gold standard and the future of bitcoin. He’s right that Strategy’s STRC product in many ways imitates the consols; irredeemable, perpetual debt, issued at par, with…
Share
BitcoinEthereumNews2025/09/18 02:12
Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent?

Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent?

The post Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent? appeared on BitcoinEthereumNews.com. In brief The White House registered aliens.gov
Share
BitcoinEthereumNews2026/03/19 05:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26